Harmony Biosciences (NASDAQ:HRMY - Get Free Report) had its price target cut by Mizuho from $52.00 to $42.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Mizuho's target price suggests a potential upside of 22.88% from the company's current price.
A number of other equities research analysts also recently weighed in on the stock. Oppenheimer reaffirmed an "outperform" rating and set a $59.00 price objective (up previously from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Needham & Company LLC reduced their target price on Harmony Biosciences from $52.00 to $50.00 and set a "buy" rating for the company in a report on Wednesday, February 19th. Cantor Fitzgerald lifted their target price on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an "overweight" rating in a research note on Wednesday, October 30th. HC Wainwright reaffirmed a "buy" rating and issued a $75.00 price target on shares of Harmony Biosciences in a research report on Wednesday, February 19th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Harmony Biosciences in a research report on Tuesday, February 11th. They set a "buy" rating and a $55.00 target price on the stock. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $53.67.
Read Our Latest Research Report on HRMY
Harmony Biosciences Stock Down 1.1 %
HRMY stock traded down $0.38 during midday trading on Thursday, hitting $34.18. 731,898 shares of the company's stock were exchanged, compared to its average volume of 578,772. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of 16.20, a price-to-earnings-growth ratio of 0.47 and a beta of 0.80. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The firm has a 50 day moving average price of $36.57 and a 200-day moving average price of $35.81. Harmony Biosciences has a 12-month low of $28.14 and a 12-month high of $41.61.
Insider Buying and Selling at Harmony Biosciences
In other news, CFO Sandip Kapadia sold 25,000 shares of the company's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $40.18, for a total value of $1,004,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jeffrey Dierks sold 1,629 shares of the business's stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $38.02, for a total transaction of $61,934.58. The disclosure for this sale can be found here. In the last three months, insiders have sold 72,452 shares of company stock worth $2,831,679. Company insiders own 30.80% of the company's stock.
Institutional Investors Weigh In On Harmony Biosciences
Institutional investors have recently added to or reduced their stakes in the stock. Hillsdale Investment Management Inc. lifted its holdings in shares of Harmony Biosciences by 0.4% in the fourth quarter. Hillsdale Investment Management Inc. now owns 68,000 shares of the company's stock valued at $2,340,000 after purchasing an additional 300 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Harmony Biosciences by 21.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company's stock worth $80,000 after acquiring an additional 360 shares in the last quarter. O Shaughnessy Asset Management LLC raised its holdings in shares of Harmony Biosciences by 2.1% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 20,450 shares of the company's stock valued at $704,000 after purchasing an additional 420 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company's stock worth $31,000 after purchasing an additional 436 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its holdings in Harmony Biosciences by 28.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock worth $80,000 after purchasing an additional 519 shares during the last quarter. 86.23% of the stock is owned by institutional investors.
Harmony Biosciences Company Profile
(
Get Free Report)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Further Reading
Before you consider Harmony Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.
While Harmony Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
